What were the main drivers of Johnson & Johnson's sales growth in the third quarter of 2001?

Sales growth was driven by strong performance across all business segments: Consumer, Pharmaceutical, and Medical Devices & Diagnostics. Key contributors included the Pharmaceutical segment with products like PROCRIT/EPREX and REMICADE, and the Medical Devices & Diagnostics segment with products from Cordis, DePuy, and LifeScan. The Consumer segment also saw growth from brands like NEUTROGENA and AVEENO.

How did the merger with ALZA Corporation impact the company's financial statements?

The merger with ALZA Corporation, completed in June 2001, was accounted for using the pooling of interests method, requiring restatement of prior financial statements. The filing notes special charges of $126 million after-tax related to restructuring and deal costs associated with the ALZA merger, which impacted net earnings for the nine-month period.

What is the company's current liquidity position?

Johnson & Johnson's liquidity has improved significantly. Cash and current marketable securities increased by $1.46 billion in the first nine months of 2001, reaching $8.21 billion. Total borrowings decreased by $1.83 billion. Net cash (cash and current marketable securities net of debt) stood at $5.39 billion as of September 30, 2001, a substantial increase from $2.11 billion at the end of 2000.

Are there any significant legal proceedings that could materially impact the company?

The company is involved in numerous legal proceedings, including product liability cases, particularly concerning the drug Propulsid. While the company believes its insurance and reserves are adequate, the outcome of litigation, especially concerning Propulsid and potential class actions, remains uncertain. An unfavorable outcome in the arbitration proceeding concerning EPO license rights could also have a material adverse effect.

JNJ 10-Q Filed Nov 13, 2001

Summary

Johnson & Johnson's (JNJ) third-quarter 2001 filing shows robust performance, with consolidated sales reaching $8.24 billion, an increase of 10.8% year-over-year, and net earnings climbing 15.6% to $1.53 billion. This growth was driven by strong performances across all segments: Consumer, Pharmaceutical, and Medical Devices & Diagnostics. The company also highlighted significant operational sales growth, particularly in its Pharmaceutical segment, fueled by key products like PROCRIT/EPREX and REMICADE, and the recent acquisition of ALZA Corporation. From a financial health perspective, JNJ demonstrated improved liquidity and a strengthened balance sheet. Net cash (cash and marketable securities minus debt) increased significantly to $5.39 billion. Furthermore, total debt as a percentage of total capital decreased from 18.6% to 10.6%, indicating a more conservative capital structure. The company also announced a regular quarterly dividend of $0.18 per share, underscoring its commitment to returning value to shareholders.

Key Highlights

1Consolidated sales for Q3 2001 grew by 10.8% to $8.24 billion, compared to $7.44 billion in Q3 2000.
2Net earnings increased by 15.6% to $1.53 billion in Q3 2001, up from $1.32 billion in Q3 2000.
3The Pharmaceutical segment showed particularly strong operational sales growth of 17.4% in Q3 2001.
4The company successfully completed the merger with ALZA Corporation in Q2 2001, which is expected to enhance its drug delivery technologies and product portfolio.
5Liquidity improved, with cash and marketable securities (net of debt) reaching $5.39 billion as of September 30, 2001.
6Total debt as a percentage of total capital decreased to 10.6% from 18.6% at year-end 2000.
7A regular quarterly dividend of $0.18 per share was declared, reflecting continued shareholder returns.

JOHNSON & JOHNSON Quarterly Report for Q3 Ended Sep 30, 2001

Summary

Key Highlights

Frequently Asked Questions